In this approach, T lymphocytes are genetically engineered to express a CAR that efficiently directs T cells to recognize and eliminate specific surface antigens on malignant tumor cells in an HLA-independent manner.[26] Therefore, human-derived anti-BCMA CAR-T cell therapy may enhance the proliferation and efficacy of these cells. This evidence concerns the gene TNFRSF17 and cancer.